|
2025-03-03 |
2025-02-27 |
B
Purchase
|
SCARLETT JOHN A
Chairman, President and CEO
Executive Director
|
12,500
+inf%
1.77
USD 22,063
|
12,500
+inf%
|
1.77
|
USD 22,063
|
|
|
2025-03-03 |
2025-02-27 |
B
Purchase
|
Ziegler James
EVP, Chief Commercial Officer
Officer
|
100,000
+inf%
1.60
USD 160,000
|
100,000
+inf%
|
1.60
|
USD 160,000
|
|
|
2025-03-03 |
2025-02-27 |
B
Purchase
|
Samuels Scott Alan
EVP, Chief Legal Officer
Officer
|
15,000
+128.4%
1.61
USD 24,150
|
15,000
+128.4%
|
1.61
|
USD 24,150
|
|
|
2024-07-10 |
2024-07-08 |
S
Sale
|
GRETHLEIN ANDREW J
EVP, Chief Operating Officer
Officer
|
674,348
-100.0%
4.56
USD 3,073,004
|
674,348
-100.0%
|
4.56
|
USD 3,073,004
|
|
|
2024-06-12 |
2024-06-10 |
S
Sale
|
Kapur Anil
EVP, Corp Strategy & CCO
Officer
|
421,875
-100.0%
4.65
USD 1,959,609
|
421,875
-100.0%
|
4.65
|
USD 1,959,609
|
|
|
2024-06-12 |
2024-06-10 |
S
Sale
|
Feller Faye
EVP, Chief Medical Officer
Officer
|
287,900
-100.0%
4.63
USD 1,334,129
|
287,900
-100.0%
|
4.63
|
USD 1,334,129
|
|
|
2024-06-05 |
2024-06-04 |
PS
Planned sale
|
SCARLETT JOHN A
Chairman, President and CEO
Executive Director
|
600,000
-50.0%
4.00
USD 2,400,000
|
600,000
-50.0%
|
4.00
|
USD 2,400,000
|
|
|
2024-05-17 |
2024-05-15 |
PS
Planned sale
|
LAWLIS V BRYAN
Non-Executive Director
|
35,000
-100.0%
3.75
USD 131,250
|
35,000
-100.0%
|
3.75
|
USD 131,250
|
|
|
2023-08-24 |
2023-08-24 |
B
Purchase
|
O'Farrell Elizabeth G.
Non-Executive Director
|
6,579
+33.5%
2.28
USD 15,000
|
6,579
+33.5%
|
2.28
|
USD 15,000
|
|
|
2023-08-24 |
2023-08-24 |
B
Purchase
|
O'Farrell Elizabeth G.
Non-Executive Director
|
6,607
+825.9%
2.28
USD 15,064
|
6,607
+825.9%
|
2.28
|
USD 15,064
|
|
|
2023-05-11 |
2023-05-11 |
PS
Planned sale
|
LAWLIS V BRYAN
Non-Executive Director
|
35,000
-100.0%
3.00
USD 105,000
|
35,000
-100.0%
|
3.00
|
USD 105,000
|
|
|
2023-05-01 |
2023-05-01 |
PS
Planned sale
|
Molineaux Susan
Non-Executive Director
|
35,000
-100.0%
2.48
USD 86,800
|
35,000
-100.0%
|
2.48
|
USD 86,800
|
|
|
2023-02-10 |
2023-02-10 |
PS
Planned sale
|
SCARLETT JOHN A
Chairman, President and CEO
Executive Director
|
446,668
-100.0%
3.00
USD 1,340,004
|
446,668
-100.0%
|
3.00
|
USD 1,340,004
|
|
|
2023-02-10 |
2023-02-09 |
PS
Planned sale
|
GRETHLEIN ANDREW J
EVP, Chief Operating Officer
Officer
|
234,719
-100.0%
3.03
USD 711,199
|
234,719
-100.0%
|
3.03
|
USD 711,199
|
|
|
2023-02-10 |
2023-02-09 |
PS
Planned sale
|
GRETHLEIN ANDREW J
EVP, Chief Operating Officer
Officer
|
150,000
-39.0%
3.03
USD 454,500
|
150,000
-39.0%
|
3.03
|
USD 454,500
|
|
|
2023-02-10 |
2023-02-09 |
PS
Planned sale
|
SCARLETT JOHN A
Chairman, President and CEO
Executive Director
|
446,666
-100.0%
3.03
USD 1,353,398
|
446,666
-100.0%
|
3.03
|
USD 1,353,398
|
|
|
2023-02-10 |
2023-02-08 |
PS
Planned sale
|
Bloom Olivia Kyusuk
EVP, Chief Financial Officer
Officer
|
400,000
-84.3%
3.08
USD 1,232,000
|
400,000
-84.3%
|
3.08
|
USD 1,232,000
|
|
|
2023-02-10 |
2023-02-08 |
PS
Planned sale
|
SCARLETT JOHN A
Chairman, President and CEO
Executive Director
|
446,666
-100.0%
3.08
USD 1,375,731
|
446,666
-100.0%
|
3.08
|
USD 1,375,731
|
|
|
2020-08-24 |
2020-08-21 |
B
Purchase
|
O'Farrell Elizabeth G.
Non-Executive Director
|
17,441
+792.8%
1.73
USD 30,173
|
17,441
+792.8%
|
1.73
|
USD 30,173
|
|
|
2020-01-13 |
2020-01-10 |
B
Purchase
|
O'Farrell Elizabeth G.
|
2,200
+inf%
1.34
USD 2,948
|
2,200
+inf%
|
1.34
|
USD 2,948
|
|
|
2020-01-13 |
2020-01-10 |
B
Purchase
|
O'Farrell Elizabeth G.
|
800
+inf%
1.35
USD 1,080
|
800
+inf%
|
1.35
|
USD 1,080
|
|
|
2019-04-10 |
2019-04-09 |
PS
Planned sale
|
BEHRS MELISSA KELLY
EVP, Chief Business Officer
|
120,635
-100.0%
2.00
USD 241,270
|
120,635
-100.0%
|
2.00
|
USD 241,270
|
|
|
2018-09-13 |
2018-09-13 |
PS
Planned sale
|
Spiegel Robert J.
Non-Executive Director
|
35,000
-34.8%
6.85
USD 239,750
|
35,000
-34.8%
|
6.85
|
USD 239,750
|
|
|
2018-09-13 |
2018-09-13 |
PS
Planned sale
|
Spiegel Robert J.
Non-Executive Director
|
35,000
-34.8%
6.85
USD 239,750
|
35,000
-34.8%
|
6.85
|
USD 239,750
|
|
|
2018-09-13 |
2018-09-13 |
PS
Planned sale
|
Spiegel Robert J.
Non-Executive Director
|
35,000
-34.8%
6.85
USD 239,750
|
35,000
-34.8%
|
6.85
|
USD 239,750
|
|
|
2018-09-13 |
2018-09-13 |
PS
Planned sale
|
Spiegel Robert J.
Non-Executive Director
|
15,000
-18.6%
6.85
USD 102,750
|
15,000
-18.6%
|
6.85
|
USD 102,750
|
|
|
2018-09-13 |
2018-09-13 |
PS
Planned sale
|
Spiegel Robert J.
Non-Executive Director
|
10,000
-13.2%
6.85
USD 68,500
|
10,000
-13.2%
|
6.85
|
USD 68,500
|
|
|
2018-09-13 |
2018-09-13 |
PS
Planned sale
|
Spiegel Robert J.
Non-Executive Director
|
45,000
-40.7%
6.85
USD 308,250
|
45,000
-40.7%
|
6.85
|
USD 308,250
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
37,500
-100.0%
4.51
USD 169,125
|
37,500
-100.0%
|
4.51
|
USD 169,125
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
112,500
-100.0%
4.51
USD 507,375
|
112,500
-100.0%
|
4.51
|
USD 507,375
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
131,250
-100.0%
4.51
USD 591,938
|
131,250
-100.0%
|
4.51
|
USD 591,938
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
420,000
-100.0%
4.51
USD 1,894,200
|
420,000
-100.0%
|
4.51
|
USD 1,894,200
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
200,000
-100.0%
4.51
USD 902,000
|
200,000
-100.0%
|
4.51
|
USD 902,000
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
425,000
-100.0%
4.51
USD 1,916,750
|
425,000
-100.0%
|
4.51
|
USD 1,916,750
|
|
|
2018-08-24 |
2018-08-24 |
PS
Planned sale
|
ROSENFIELD STEPHEN
EVP, Genl Counsel & Secretary
Officer
|
36,000
-100.0%
4.51
USD 162,360
|
36,000
-100.0%
|
4.51
|
USD 162,360
|
|
|
2015-03-19 |
2015-03-18 |
S
Sale
|
Hofstaetter Thomas
Non-Executive Director
|
70,000
-72.5%
4.10
USD 287,000
|
70,000
-72.5%
|
4.10
|
USD 287,000
|
|
|
2014-05-12 |
2014-05-09 |
B
Purchase
|
BRADBURY DANIEL
Non-Executive Director
|
142,776
+inf%
1.75
USD 249,858
|
142,776
+inf%
|
1.75
|
USD 249,858
|
|
|
2013-04-01 |
2013-04-01 |
B
Purchase
|
SCARLETT JOHN A
President and CEO
Executive Director
|
50,000
+66.7%
1.03
USD 51,500
|
50,000
+66.7%
|
1.03
|
USD 51,500
|
|
|
2013-01-22 |
2013-01-17 |
S
Sale
|
BEHRS MELISSA KELLY
SVP Alliance and Prog Mgmt
Officer
|
28,292
-100.0%
1.65
USD 46,569
|
28,292
-100.0%
|
1.65
|
USD 46,569
|
|
|
2011-11-23 |
2011-11-22 |
B
Purchase
|
KILEY THOMAS
Non-Executive Director
|
64,275
+25.7%
1.56
USD 100,269
|
64,275
+25.7%
|
1.56
|
USD 100,269
|
|
|
2011-10-06 |
2011-10-05 |
B
Purchase
|
KILEY THOMAS
Non-Executive Director
|
50,000
+107.2%
2.03
USD 101,500
|
50,000
+107.2%
|
2.03
|
USD 101,500
|
|
|
2009-02-03 |
2009-02-02 |
S
Sale
|
BEHRS MELISSA KELLY
SVP Oncology
Officer
|
14,765
-100.0%
8.12
USD 119,892
|
14,765
-100.0%
|
8.12
|
USD 119,892
|
|
|
2009-01-30 |
2009-01-30 |
S
Sale
|
WALKER JOHN PETER
Non-Executive Director
|
48,617
-55.4%
8.28
USD 402,549
|
48,617
-55.4%
|
8.28
|
USD 402,549
|
|
|
2009-01-30 |
2009-01-29 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
25,000
-20.1%
7.08
USD 177,000
|
25,000
-20.1%
|
7.08
|
USD 177,000
|
|
|
2009-01-30 |
2009-01-29 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
5,489
-4.2%
7.14
USD 39,191
|
5,489
-4.2%
|
7.14
|
USD 39,191
|
|
|
2008-11-05 |
2008-11-05 |
S
Sale
|
BEHRS MELISSA KELLY
SVP Oncology
Officer
|
23,845
-21.2%
4.05
USD 96,572
|
23,845
-21.2%
|
4.05
|
USD 96,572
|
|
|
2008-01-04 |
2008-01-04 |
S
Sale
|
EARP DAVID
SVP Bus Dev, Chief Patnt Couns
Officer
|
8,911
-5.4%
5.34
USD 47,585
|
8,911
-5.4%
|
5.34
|
USD 47,585
|
|
|
2008-01-04 |
2008-01-04 |
S
Sale
|
BEHRS MELISSA KELLY
SVP Oncology
Officer
|
8,911
-8.6%
5.34
USD 47,585
|
8,911
-8.6%
|
5.34
|
USD 47,585
|
|
|
2008-01-04 |
2008-01-04 |
S
Sale
|
LEBKOWSKI JANE
SVP Regen Medicine
Officer
|
8,911
-5.7%
5.34
USD 47,585
|
8,911
-5.7%
|
5.34
|
USD 47,585
|
|
|
2008-01-04 |
2008-01-04 |
S
Sale
|
GREENWOOD DAVID
EVP and CFO
Officer
|
11,039
-6.0%
5.34
USD 58,948
|
11,039
-6.0%
|
5.34
|
USD 58,948
|
|
|
2008-01-04 |
2008-01-04 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
8,911
-6.9%
5.34
USD 47,585
|
8,911
-6.9%
|
5.34
|
USD 47,585
|
|
|
2008-01-04 |
2008-01-04 |
S
Sale
|
OKARMA THOMAS
President and CEO
Officer
|
13,166
-3.5%
5.34
USD 70,306
|
13,166
-3.5%
|
5.34
|
USD 70,306
|
|
|
2007-11-13 |
2007-11-12 |
S
Sale
|
GREENWOOD DAVID
EVP and CFO
Officer
|
4,000
-2.2%
7.20
USD 28,800
|
4,000
-2.2%
|
7.20
|
USD 28,800
|
|
|
2007-05-21 |
2007-05-18 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
3,000
-5.0%
9.13
USD 27,390
|
3,000
-5.0%
|
9.13
|
USD 27,390
|
|
|
2007-05-21 |
2007-05-18 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
9,000
-13.0%
9.15
USD 82,350
|
9,000
-13.0%
|
9.15
|
USD 82,350
|
|
|
2007-05-21 |
2007-05-18 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
9,000
-11.5%
9.21
USD 82,890
|
9,000
-11.5%
|
9.21
|
USD 82,890
|
|
|
2007-05-21 |
2007-05-18 |
S
Sale
|
HARLEY CALVIN
VP and CSO
Officer
|
9,000
-10.3%
9.22
USD 82,980
|
9,000
-10.3%
|
9.22
|
USD 82,980
|
|
|
2006-01-10 |
2006-01-09 |
S
Sale
|
GREENWOOD DAVID
Executive VP and CFO
Officer
|
12,183
-41.8%
8.56
USD 104,286
|
12,183
-41.8%
|
8.56
|
USD 104,286
|
|
|
2006-01-10 |
2006-01-09 |
S
Sale
|
LEBKOWSKI JANE
SVP, Regenerative Medicine
Officer
|
10,676
-35.7%
8.56
USD 91,387
|
10,676
-35.7%
|
8.56
|
USD 91,387
|
|
|
2006-01-10 |
2006-01-09 |
S
Sale
|
EARP DAVID
SVP Bus Dev / Chf Patent Couns
Officer
|
11,323
-35.7%
8.56
USD 96,925
|
11,323
-35.7%
|
8.56
|
USD 96,925
|
|
|
2006-01-10 |
2006-01-09 |
S
Sale
|
HARLEY CALVIN
Chief Scientific Officer
Officer
|
9,183
-53.3%
8.56
USD 78,606
|
9,183
-53.3%
|
8.56
|
USD 78,606
|
|
|
2006-01-10 |
2006-01-09 |
S
Sale
|
BEHRS MELISSA KELLY
VP, Oncology
Officer
|
8,441
-53.4%
8.56
USD 72,255
|
8,441
-53.4%
|
8.56
|
USD 72,255
|
|
|
2006-01-10 |
2006-01-09 |
S
Sale
|
OKARMA THOMAS
President and CEO
Executive Director
|
12,320
-28.1%
8.56
USD 105,459
|
12,320
-28.1%
|
8.56
|
USD 105,459
|
|
|
2005-08-01 |
2005-07-29 |
S
Sale
|
KELLY MELISSA
VP, Oncology
Officer
|
19,532
-77.4%
10.88
USD 212,508
|
19,532
-77.4%
|
10.88
|
USD 212,508
|
|
|
2005-08-01 |
2005-07-29 |
S
Sale
|
KELLY MELISSA
VP, Oncology
Officer
|
46,039
-64.6%
10.88
USD 500,904
|
46,039
-64.6%
|
10.88
|
USD 500,904
|
|
|
2005-07-21 |
2005-07-20 |
S
Sale
|
HARLEY CALVIN
Chief Scientific Officer
Officer
|
25,000
-80.9%
10.46
USD 261,410
|
25,000
-80.9%
|
10.46
|
USD 261,410
|
|
|
2005-07-21 |
2005-07-20 |
S
Sale
|
GREENWOOD DAVID
Executive VP and CFO
Officer
|
30,000
-71.5%
10.45
USD 313,500
|
30,000
-71.5%
|
10.45
|
USD 313,500
|
|
|
2005-01-14 |
2005-01-13 |
S
Sale
|
EARP DAVID
SVP Bus Dev / Chf Patent Couns
Officer
|
9,239
-33.0%
8.57
USD 79,178
|
9,239
-33.0%
|
8.57
|
USD 79,178
|
|
|
2005-01-14 |
2005-01-13 |
S
Sale
|
GREENWOOD DAVID
Executive VP, CFO
Officer
|
13,804
-53.6%
8.57
USD 118,300
|
13,804
-53.6%
|
8.57
|
USD 118,300
|
|
|
2005-01-14 |
2005-01-13 |
S
Sale
|
OKARMA THOMAS
President and CEO
Executive Director
|
14,283
-43.2%
8.57
USD 122,405
|
14,283
-43.2%
|
8.57
|
USD 122,405
|
|
|
2005-01-14 |
2005-01-13 |
S
Sale
|
LEBKOWSKI JANE
SVP, Regenerative Medicine
Officer
|
6,154
-26.4%
8.57
USD 52,740
|
6,154
-26.4%
|
8.57
|
USD 52,740
|
|
|
2005-01-14 |
2005-01-13 |
S
Sale
|
KELLY MELISSA
VP, Oncology
Officer
|
8,648
-60.2%
8.57
USD 74,113
|
8,648
-60.2%
|
8.57
|
USD 74,113
|
|
|
2005-01-14 |
2005-01-13 |
S
Sale
|
HARLEY CALVIN
Chief Scientific Officer
Officer
|
9,929
-62.7%
8.57
USD 85,092
|
9,929
-62.7%
|
8.57
|
USD 85,092
|
|
|
2004-08-18 |
2004-08-16 |
S
Sale
|
MERIX BIOSCIENCE INC
Large shareholder
|
4,086
-0.1%
5.62
USD 22,963
|
4,086
-0.1%
|
5.62
|
USD 22,963
|
|
|
2004-08-18 |
2004-08-16 |
S
Sale
|
MERIX BIOSCIENCE INC
Large shareholder
|
2,800
-0.1%
5.61
USD 15,708
|
2,800
-0.1%
|
5.61
|
USD 15,708
|
|
